Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Anti-adhesion therapies.

Simmons DL.

Curr Opin Pharmacol. 2005 Aug;5(4):398-404. Review.

PMID:
15955735
[PubMed - indexed for MEDLINE]
2.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Rudick RA, Sandrock A.

Expert Rev Neurother. 2004 Jul;4(4):571-80. Review.

PMID:
15853576
[PubMed - indexed for MEDLINE]
3.

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Rice GP, Hartung HP, Calabresi PA.

Neurology. 2005 Apr 26;64(8):1336-42. Review.

PMID:
15851719
[PubMed - indexed for MEDLINE]
4.

Natalizumab: targeting alpha4-integrins in multiple sclerosis.

Engelhardt B, Kappos L.

Neurodegener Dis. 2008;5(1):16-22. Review.

PMID:
18075270
[PubMed - indexed for MEDLINE]
5.

Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Davenport RJ, Munday JR.

Drug Discov Today. 2007 Jul;12(13-14):569-76. Epub 2007 Jun 26. Review.

PMID:
17631252
[PubMed - indexed for MEDLINE]
6.
7.

Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.

Lanzarotto F, Carpani M, Chaudhary R, Ghosh S.

Drugs. 2006;66(9):1179-89. Review.

PMID:
16827596
[PubMed - indexed for MEDLINE]
8.

Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.

Stefanelli T, Malesci A, De La Rue SA, Danese S.

Autoimmun Rev. 2008 May;7(5):364-9. doi: 10.1016/j.autrev.2008.01.002. Epub 2008 Feb 12. Review.

PMID:
18486923
[PubMed - indexed for MEDLINE]
9.

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.

Cather JC, Cather JC, Menter A.

Expert Opin Biol Ther. 2003 Apr;3(2):361-70. Review.

PMID:
12662148
[PubMed - indexed for MEDLINE]
10.

LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics.

Giblin PA, Lemieux RM.

Curr Pharm Des. 2006;12(22):2771-95. Review.

PMID:
16918410
[PubMed - indexed for MEDLINE]
11.

Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease.

Woodside DG, Vanderslice P.

BioDrugs. 2008;22(2):85-100. Review.

PMID:
18345706
[PubMed - indexed for MEDLINE]
12.

[Efalizumab].

Descamps V.

Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. Review. French.

PMID:
17053736
[PubMed - indexed for MEDLINE]
13.

The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.

Sheremata WA, Minagar A, Alexander JS, Vollmer T.

CNS Drugs. 2005;19(11):909-22. Review.

PMID:
16268663
[PubMed - indexed for MEDLINE]
14.

Interfering with leukocyte integrin activation--a novel concept in the development of anti-inflammatory drugs.

Hilden TJ, Nurmi SM, Fagerholm SC, Gahmberg CG.

Ann Med. 2006;38(7):503-11. Review.

PMID:
17101541
[PubMed - indexed for MEDLINE]
15.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024
[PubMed - indexed for MEDLINE]
16.

Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction.

Rychly J, Nebe B.

Curr Pharm Des. 2006;12(29):3799-806. Review.

PMID:
17073678
[PubMed - indexed for MEDLINE]
17.

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.

Dedrick RL, Walicke P, Garovoy M.

Transpl Immunol. 2002 May;9(2-4):181-6. Review.

PMID:
12180828
[PubMed - indexed for MEDLINE]
18.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
[PubMed - indexed for MEDLINE]
19.

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R.

J Clin Pharmacol. 2006 Jan;46(1):10-20. Review.

PMID:
16397279
[PubMed - indexed for MEDLINE]
20.

Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action.

Zimmerman T, Blanco FJ.

Curr Pharm Des. 2008;14(22):2128-39. Review.

PMID:
18781967
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk